Skip to main content

Mount Sinai to Use JPT Peptide Arrays in Food Allergy Biomarker Collaboration

This article has been updated to correct an error in the headline.
 
NEW YORK (GenomeWeb News) - JPT Peptide Technologies, a subsidiary of Berlin-based pharmaceutical company Jerini, said today that Mount Sinai School of Medicine will use its PepStar peptide-microarray platform as part of a biomarker discovery collaboration.
 
JPT and MSSM will use the peptide arrays to discover B-cell epitopes for use in developing vaccines and diagnostics in the field of food allergies.
 
Researchers at MSSM will use the arrays to study samples of “diverse patient populations suffering from various kinds of food allergies,” the company said in a statement.
 
JPT will use its peptide synthesis and screening platform to generate large numbers of peptides derived from food allergens, which will be used to produce identical copies of peptide microarrays for incubation with patient samples.
 
"Our experience has shown the use of peptide microarrays to be a highly efficient and cost-effective tool for the systematic screening of the B-cell response of complex patient populations,” said Hugh Sampson, director of the Jaffe Food Allergy Institute at MSSM, in a statement. “In this context, JPT's platform is unique in both its synthesis power for tens of thousands of peptides and its suitability for resulting microarrays for the purpose of biomarker identification by means of patient sera."

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.